COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Long-Term Follow-up Study for Patients Previously Treated With JCAR015

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02813252
Recruitment Status : Active, not recruiting
First Posted : June 24, 2016
Last Update Posted : May 4, 2020
Information provided by (Responsible Party):
Juno Therapeutics, a Subsidiary of Celgene

Brief Summary:
This study will provide long-term follow-up for patients who have received treatment with JCAR015 in a previous clinical trial. In this study, patients will be followed for up to 15 years after their last dose of JCAR015 for evaluation of delayed adverse events, presence of persisting JCAR015 vector sequences, and survival.

Condition or disease Intervention/treatment
Acute Lymphoblastic Leukemia Genetic: JCAR015

Layout table for study information
Study Type : Observational
Actual Enrollment : 15 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Long-Term Follow-up Protocol for Subjects Treated With JCAR015
Actual Study Start Date : August 30, 2016
Estimated Primary Completion Date : September 2032
Estimated Study Completion Date : September 2032

Group/Cohort Intervention/treatment
Patients who received previous treatment with JCAR015
Genetic: JCAR015
No study drug is administered in this study. Patients who received JCAR015 in a previous trial will be evaluated in this trial for long-term safety and efficacy.

Primary Outcome Measures :
  1. Proportion of patients with adverse events [ Time Frame: Every year for up to 15 years post-treatment ]
  2. Proportion of patients with detectable JCAR015 vector sequences during first 5 years post-treatment [ Time Frame: Every 6 months for the first 5 years post-treatment ]
  3. Proportion of patients with detectable JCAR015 vector sequences between 5 and 15 years post-treatment [ Time Frame: Every year from 5 years post-treatment to up to 15 years post-treatment ]
  4. Survival [ Time Frame: Up to 15 years ]

Biospecimen Retention:   Samples With DNA
Genomic DNA prepared from peripheral blood mononuclear cells

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients previously treated with JCAR015 in a prior clinical trial

Inclusion criteria:

  • Patients who have received at least one dose of JCAR015 in a previous treatment protocol.
  • Patients who have provided informed consent for the long-term follow-up study prior to study participation.

Exclusion criteria:

  • None. All patients who have previously received JCAR015 treatment are eligible for this long-term follow-up study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02813252

Layout table for location information
United States, Illinois
Robert H Lurie Comprehensive Cancer Center of Northwestern University
Chicago, Illinois, United States, 60611
United States, Maryland
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
Baltimore, Maryland, United States, 21287
United States, Missouri
Washington University School of Medicine
Saint Louis, Missouri, United States, 63110
United States, New York
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
Sponsors and Collaborators
Juno Therapeutics, a Subsidiary of Celgene
Layout table for investigator information
Study Director: Nikolaus Trede, MD, PhD JunoTherapeutics, Inc.
Layout table for additonal information
Responsible Party: Juno Therapeutics, a Subsidiary of Celgene Identifier: NCT02813252    
Other Study ID Numbers: 015002
First Posted: June 24, 2016    Key Record Dates
Last Update Posted: May 4, 2020
Last Verified: April 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Juno Therapeutics, a Subsidiary of Celgene:
long-term follow-up
chimeric antigen receptor (CAR) T cells
Additional relevant MeSH terms:
Layout table for MeSH terms
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia, Lymphoid
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases